Previous
CRF Health’s TrialMax Touch® Selected by Leading Specialty Pharmaceutical Company for Pediatric Rare Disease Phase II Study
CRF Health’s TrialMax Touch® Selected by Leading Specialty Pharmaceutical Company for Pediatric Rare Disease Phase II Study

Next
CRF Health’s TrialMax Touch® Solution Selected for Landmark Global Oncology Study
CRF Health’s TrialMax Touch® Solution Selected for Landmark Global Oncology Study

CRF Health's TrialMax Touch® solution has been selected by a top ten pharmaceutical company for a landmark ...